{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-023834","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.003677+00:00","generated_at":"2026-06-01T04:16:08.887643+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LIXTE collaborates with Roche and NKI on trial combining LB-100 with atezolizumab in MSI Low colon cancer","bullets":["Trial (NCT06012734) will test LB-100 plus Roche's PD-L1 inhibitor atezolizumab in immunotherapy-unresponsive MSI Low metastatic colon cancer.","LIXTE provides LB-100; Roche provides atezolizumab via imCORE Network; NKI is principal investigator.","About 85% of colon cancers are MSI Low; LB-100 may sensitize these tumors to immunotherapy, expanding treatment options.","This is second recent pharma-backed trial combining LB-100 with immunotherapy; GSK is funding a separate trial in clear cell ovarian cancer.","New pre-clinical data in EMBO Reports showed LB-100 can turn immunologically 'cold' tumors 'hot'."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-023834","json":"https://secwatch.observer/filing/0001493152-24-023834.json","markdown":"https://secwatch.observer/filing/0001493152-24-023834.md","text":"https://secwatch.observer/filing/0001493152-24-023834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224023834/0001493152-24-023834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224023834/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:16:08.887643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}